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PDB72 QUALITY ADJUSTED LIFE YEARS LOSS DUE TO TYPE 2 DIABETES IN SOUTH KOREA
Jo MW 1 , Lee WJ 1 , Noh JH 2 , Choi Y 3 , Song KH 4 1 University of Ulsan, Seoul, South Korea, 2 Inje University Ilsan Paik Hospital, Ilsan, GyeonggiDo, South Korea, 3 sanofi-aventis Korea, Seoul, South Korea, 4 Kunkuk University Hospital, Seoul, South Korea OBJECTIVES: This study was conducted to estimate quality adjusted life years (QALYs) loss due to diabetes in type 2 diabetic patients of South Korea. METHODS: In order to obtain QALYs loss due to morbidity of type 2 diabetes (T2D), we firstly estimated utility weight difference between T2D patients and non-diabetic subjects by sex and age groups. We consecutively recruited T2D patients aged 20 or over who visited three university hospitals in Seoul and Ilsan from October 2007 to January 2008 and non-diabetic subjects who took a medical examination from June 2008 to Jan 2009 in same hospitals. Utility weight differences on sex and age groups were calculated using the EuroQoL EQ-5D and Korean valuation set, and then QALY losses was estimated using the utilities and the number of T2D patients in 2003 reported by the Korean Diabetes Basic Statistics Study. QALY losses due to T2D mortality corresponded to life expectancy of the death caused T2D from the life table and the Korean Death Certificate in 2003 multiplied by utility weights of healthy people by sex and age groups from the 3 rd Korea National Health and Nutrition Examination Survey (2005) . We considered a discount rate as 5%. RESULTS: Total 1,072 T2D patients and 387 non-diabetic subjects participated in this survey. Maximum difference between T2D patients and non-diabetic subjects was 0.0418 and minimum difference was 0.0095 by subgroups. QALY loss estimates due to T2D morbidity were about 35, 125 (TLV) . METHODS: To retrieve the HTA reports, a search was executed using the agencies websites with the following keywords: pioglitazone, rosiglitazone, sitagliptin, vildagliptin, exenatide, glargine, detemir, aspart, glulisine and lispro. If a report contained several drugs each drug was counted separately although a decision could involve a class of drugs. Decision parameters were clustered in three categories: efficacy, safety and health economics where each assessment could contain multiple parameters. Overall recommendation was classified in three categories: recommended restricted recommended and not recommended in relation to indication based on marketing authorisation. RESULTS: 35 reports were identified with 49 assessments. Twelve assessments lead to recommendation (24%), 23 to restricted recommendation (47%) and fourteen to no recommendation (29%). Reasons for recommending a treatment contained in 83% of cases one or more arguments related to efficacy, 33% to safety, and 66% to health economic aspects of drugs. Reasons for restricted recommendation were 70%, 39%, and 60%, and for not recommended were 100%, 57% and 21% respectively. Within each decision parameter the most common reason for restricting the market authorization indication was related to the drug not being cost-effective (57%). The most common reason for not recommending a drug was lack of long term data on efficacy (86%).
CONCLUSIONS:
Despite that large variations in results between agencies were observed, data demonstrating efficacy of the drug appeared to be the most important factor in getting a recommendation for type 2 diabetes treatment. A high incremental cost-effectiveness ratio was likely to lead to restrictions in indication (NICE, SMC and TLV) whereas lack of long term data could lead to the drug not being recommended (IQWIG and CVZ).
PDB74 ETHICAL DILEMMAS OF PHARMACOLOGICAL TREATMENT AND SELF MANAGEMENT OF DIABETES-A REVIEW OF THE LITERATURE
Jensen RCØ 1 , Kaas C 2 , Mondher T 3 , Hemels M 4 1 Novo Nordisk A/S, Bagsvaerd, Denmark, 2 Copenhagen University, Copenhagen, Denmark, 3 University Claude Bernard Lyon, Lyon, France, 4 Novo Nordisk A/S, bagsvaerd, Denmark OBJECTIVES: There is increasing focus on the ethical analysis in Health Technology Assessments (HTA). Due to the escalating epidemic of diabetes, diabetes has become an urgent health concern. We therefore systematically reviewed published articles describing the ethical aspects of pharmacological treatment and self management of diabetes. METHODS: PubMed was searched from inception to 2009 using the following combinations of keywords: ethics AND diabetes NOT screening NOT transplant. Articles were initially screened for relevance by reading title and abstract. If deemed appropriate, by two independent reviewers, full copies of the remaining articles were retrieved for further review. RESULTS: Out of 336 articles, only six studies were deemed appropriate. The main reason for this high level of rejected articles was that the majority of identified articles commented on the ethical approval in connection to conducting clinical studies rather than on the ethical aspects of implementing and using the specific technology. One study described the ethical concern related to the costly late complications of diabetes compared to preventing late complications by prescribing and reimbursing insulin. Other ethical issues concerned self management and the transferral of responsibility from physician to patient and the patient's capabilities for self management. For people with impaired glucose tolerance there were also ethical issues related to initiating a preventive pharmacological treatment of the "otherwise well". Lastly, there is an ethical issue between the normative gold standard for a healthy and moral lifestyle and a culture of self that values authenticity and originality. CONCLUSIONS: Due to the escalating prevalence of diabetes and emphasis on ethical analysis in HTAs, both payers and the industry needs to get a better understanding of the ethical aspects of self management and pharmacological treatment of diabetes. More research should be allocated towards investigating the ethical aspects of self management and pharmacological treatment of diabetes.
PDB75 APPLICATION OF HTA TO ANTIDIABETIC DRUG FORMULARY DECISIONS
Andreykiv M, Wiebinga C Quintiles Consulting, Hoofddorp, The Netherlands OBJECTIVES: To compare Health Technology Assessments (HTAs) and reimbursement decisions of a novel antidiabetic drug class, by health care agencies worldwide. METHODS: We conducted manual searches of 54 health care agencies' web sites from January 2008 to May 2009. HTAs regarding diabetes were collected and each was assessed for date, type (e.g., single drug versus class review) and scope (e.g., medicine name). Using a standardized set of categorical criteria, we investigated recommendations, as well as presence of supporting evidence (e.g., reported outcome measures, information sources, and key decision drivers). RESULTS: A total of 21 completed diabetes assessments were assessed. Data were retrieved from 9 agencies in 9 countries. The agencies published 21 assessments on diabetes during the review period; including 4 clinical guidelines, 9 single drug appraisals and 8 class reviews. Of the 6 agencies (9 publications) that evaluated DPP-4 inhibitors, 2 recommended the drug not be listed or funded (CADTH, AHTAPol) and 4 recommended restricted use (PBAC, SMC, CVZ and NICE). The most common reason for agency's disinclination for listing/funding was insufficient information on the effectiveness and cost-effectiveness in the specified patient population. There are more than 100 HTAs ongoing in the endocrine nutritional and metabolic therapeutic area, approximately half of them (49 projects) concern diabetes, 21 of which evaluate pharmacological treatment of diabetes (8 countries, 11 agencies). CONCLUSIONS: Diabetes prevalence is on the rise, attracting increasing attention from health care agencies. Despite using similar data sources variable outcomes suggest to us that agencies are applying different weightings in their assessment process. The apparent failure to demonstrate effectiveness in specified populations suggests late segmentation by manufacturers and insufficient resourcing to generate data. This is often due to late payer requests for such analyses motivated by financial considerations. Early segmentation and engagement with payers is thus critical for HTA success.
PDB76 ETHICAL ANALYSES IN HEALTH TECHNOLOGY ASSESSMENTS OF DIABETES TREATMENTS
Kaas C 1 , Jensen RCØ 2 , Adalsteinsson E 3 1 Copenhagen University, Copenhagen, Denmark, 2 Novo Nordisk A/S, Bagsvaerd, Denmark, 3 Novo Nordisk A/S, Soeborg, Denmark OBJECTIVES: Health Technology Assessment (HTA) is mostly known for its health economic properties even though it is a multidisciplinary form of policy research examining short-and long-term consequences of the application of a health technology. There is an increased focus on ethical analyses in HTA. A descriptive analysis was conducted on diabetes HTA reports describing ethical analyses. METHODS: The NHS Centre for Reviews and Dissemination HTA database (http://www.crd.york. ac.uk/crdweb/) was searched (1991-2009) using the keyword 'diabet*'. HTA reports in English language assessing diabetes treatments were included and screened for any type of ethical analyses. RESULTS: Of 263 HTA reports identified in the initial search, 60 met the inclusion criteria. 4 reports included a type of ethical analysis (2 from CADTH, Canada; 1 from AHTA, Australia and 1 from NZHTA, New Zealand). CADHT conducted ethical analyses on short-and long-acting insulin analogues respectively, concluding that both types of insulin analogues did not exacerbatemight even better-the psychosocial issues of diabetes, however more quality-of-life -the psychosocial issues of diabetes, however more quality-of-life the psychosocial issues of diabetes, however more quality-of-life evidence were needed. In AHTA's assessment of a continuous glucose monitoring device they described equity and access issues related to costs, and that the device could not replace standard of care, but should be used as an adjunct. NZHTA's assessment of continuous glucose monitoring devices was also related to equity concerns, concluding a need for more affordable devices. CONCLUSIONS: Ethical analyses are sparse in diabetes, despite stated objectives of best practice and HTA definitions. In the identified cases, ethical analyses were targeted to meet patients' needs as well as a tool to restrict access for the purpose of fair distribution in government funded health care systems. Further research on the methods of ethical analyses is warranted as well as the formulation of guidelines to fully estimate the value and ensure an optimal role for ethical analyses in HTA. The ongoing Cardiovascular (CV) Risk Evaluation in people with Type-2 diabetes mellitus (T2DM) on Insulin Therapy (CREDIT) study is assessing the effect of insulin on the risk of vascular events. METHODS: CREDIT is a 4-year, 314 centre, non-interventional trial in North America, Europe and Asia, and includes 3031 people with T2DM who recently started basal and/or short-acting insulin, premix insulin or another insulin type. This analysis examines and compares the characteristics between groups starting basal (n 1563), basal short-acting (n 444), shortacting (n 221), premixed (n 700) or another (n 103) insulin. RESULTS: Demographic and diabetes characteristics were reasonably balanced between the insulin groups, although those receiving basal plus short-acting insulin or premix had a trend to higher baseline HbA1c levels vs other insulin types (basal, 9.2 1.8%; basal short-acting, 10.1 2.2%; short-acting, 9.4 2.0%; premix, 9.9 2.0%; other, 9.1 2.0%). While the majority had previously used oral glucose lowering drugs (OGLDs) (basal, 97%; basal short-acting, 83%; short-acting, 83%; premix, 94%; other, 85%), differences in the numbers continuing OGLDs when beginning insulin were found. Continued use of OGLDs was highest wth basal insulin (89%) versus the other insulins (basal short-acting, 36%; short-acting, 45%; premix, 62%; other, 34%). However, the distribution of types of OGLD used before insulin was similar between the groups. There are no clear patterns in CV risk profile by insulin type. Previous diagnosis of hypertension (basal, 71%; basal short-acting, 65%; short-acting, 57%; premix, 69%; other, 72%), family history of CV disease (basal, 29%; basal shortacting, 25%; short-acting, 21%; premix, 23%; other, 14%) and body mass index tended to be lower in the short-acting insulin group. However, triglyceride levels were lower in the short-acting and 'other' insulin groups vs premix, basal and basal plus short-acting groups. CONCLUSIONS: People starting different insulins have
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